.
151P : 25cm.

Place hold on Studying the possible role of HCV genotypes and quasispecies in relation to peginterferon treatment /

.
94P. : 25cm.

Place hold on Analysis of some cell cycle regulatory molecules in chronic hepatitis C virus liver disease /

.
105 P. : 25cm.

Place hold on Liver eosinophilic infiltrate in patients with chronic hepatitis C :

.
134P : 30cm.

Place hold on Evaluation of hepatitis C virus (HCV) genotypes and prevalence of HCV associated sialadenitis in patients with chronic HCV /

.
85 P. : 25cm.

Place hold on Clinical biochemical and histological profile of chronic hepatitis C patients with normal serum aminotransferases /

.
116 P. : 25cm.

Place hold on Risk factors of interferon retinopathy in hepatitis C virus patients /

.
103 P. : 25cm.

Place hold on Laminin and syndecan-1 levels as biomarkers in patients with hepatitis C /

.
164 P. : 25cm.

Place hold on Cutaneous manifestations of interferon alpha & ribavirin therapy of hepatits C viral infection /

.
171P. : 25cm.

Place hold on New trends in the treatment of chronic hepatitis C virus infection /

.
315P. : 25cm..

Place hold on Neuropsychiatric complications of chronic hepatitis C infection in Egyptian patients /

.
214P. : 25cm.

Place hold on Evaluation of the risk of atherosclerosis in chronic hepatitis C patients /

.
188 P. ; 25cm.

Place hold on A study non - invasive method for liver fibrosis and prediction of hepatocellular carcinoma /

.
106 P. : 25cm.

Place hold on Impact of hepatitis C virological load and bilharzial antibodies on rapid virological response /

.
167P : 30cm.

Place hold on Biochemical studies of some enzyme markers and metabolites in hepatic and renal dysfunction /

.
168P. : 25cm.

Place hold on Diabetic chronic HCV patients and their response to interferon therapy /

.
116P. : 30cm.

Place hold on Serum levels of neopterin in patients with hepatitis C virus related chronic liver disease /

.
130 P. : 25cm.

Place hold on Non - invasive fibrosis markers and transient elastography versus liver biopsy as predictors for end treatment response in chronic HCV patients receiving pegylated interferon and ribavirin /

.
154 P. : 25cm.

Place hold on Detection of helicolobacter pylori in liver tissue of chronic hepatitis-C-virus patients :

.
152 P. : 25cm.

Place hold on Prevalence of hepatitis C virus among psoriatic patients /

.
128 P. : 25cm.

Place hold on Detection of protein R (PKR) gene expression in hepatocellular carcinoma (HCC) patients resulting from hepatitis C virus (HCV) infection /

.
110 P. : 25cm.

Place hold on Serum level of interfon inducible protein 10 (IP-10) as a predictor of response to treatment with peg-interferon plus ribavirin in Egyptian chronic HCV patients /

.
100P. : 25cm.

Place hold on 3 biochemical markers in blood can predict cirrhotic evolution of chronic hepatitis /

.
74 P . : 25cm.

Place hold on Value of hepatitis C core antigen in detection of chronic hepatitis C virus eradication state post treatment /

.
113 P. : 25cm.

Place hold on Immunochemical studies on nuclear matrix protein (NMP) in patients with chronic hepatitis C /

.
80 P. ; 25cm.

Place hold on Impact of direct acting anti HCV drugs (DAAs) on renal function indices in patients with chronic Hepatitis C virus (HCV) infection /

.
99 P. : 25cm.

Place hold on Protein kinase R (PKR) expression as a predictive factor for interferon response in chronic hepatitis C patients /

.
109P. : 25cm.

Place hold on Distribution and localization of the hepatic progenitor cells in chronic hepatitis C disease :

.
148 P . : 25cm.

Place hold on Oral microbiome of patients with chronic hepatitis C virus infection :

.
108 P. : 25cm.

Place hold on Viral kinetic changes after 4 weeks and its relation to response to Peg - INF therapy in chronic HCV genotype 4 patients /

.
131 P. : 25cm.

Place hold on Hemochromatosis gene polymorphism as a predictor of virological response to pegylated interferon plus ribavirin in treatment of chronic hepatitis C virus /

.
129 P. : 25cm.

Place hold on MicroRNA expression as a predictor of the success of pegylated interferon-ribavirin therapy against chronic hepatitis C in Egyptian patients /

.
63 P. ; 25cm.

Place hold on Short duration for easy to treat patients generic sofosbuvir / ledipasvir treatment of Naïve, non-cirrhotic patients with chronic HCV infection :

.
135 P. : 25cm.

Place hold on Circulating hematopoietic derived fibrocytes in chronic hepatitis C patients with liver fibrosis /

.
114 P. : 25cm.

Place hold on Biochemical studies for evaluating the impact of hepatitis C virus co-infection with schistosomiasis on liver fibrosis progression using biotechnology /

.
186 P. : 25cm.

Place hold on Ultrastructural and immunohistochemical study of hepatocytes and hepatic progenitor cells in patients with chronic hepatitis c virus infection and hepatocellular carcinoma /

.
107 P. : 25cm.

Place hold on Gene polymorphism of MxA in patients with chronic hepatitis C /

.
95 P. : 25cm.

Place hold on MicroRNA as a predictor marker for response to interferon treatment of chronic hepatitis C in Egyptian patients /

.
94P. : 25cm.

Place hold on Significance of cyclooxygenase 2 (Cox - 2) expression in patients with hepatitis c virus (HCV) chronic liver disease /

.
148P. : 25cm.

Place hold on Morphometric ultrastrutural study of nucleus and intercellular spaces in patients with chronic hepatitis C virus infection and hepatocellular carcinoma /

.
152 P. : 25cm.

Place hold on Immunomodulation of the standard treatment of chronic hepatitis C virus infection by probiotic supplement /

.
199P. : 25cm.

Place hold on Non invasive evaluation of hepatic fibrosis in patients with hepatitis C using elastography /

.
103 P. : 25cm.

Place hold on The X{u00AD}ray repair cross complementing protein 1(XRCC1) rs25487 polymorphism and susceptibility to cirrhosis in patients with chronic hepatitis C virus /

.
142 P. : 25cm .

Place hold on MicroRNA-215 as a diagnostic marker in Egyptian patients with hepatocellular carcinoma /

.
126 P. : 25cm.

Place hold on Comparative study of the effect of direct acting antivirals (DAAS) agents versus combined pegylated interferon and Ribavirin therapy on fibrosis regression in chronic HCV patients /

2025 .
170 pages : 25 cm. + .

Place hold on Correlation between vitamin D And chronic hepatitis C Virus in egyptian patients /

.
130 P. : 25cm .

Place hold on The impact of sofosbuvir containing regimens on outcomes of a cohort of Egyptian patients with chronic hepatitis c virus induced cirrhosis with mild decompensation /

.
245 Leaves : 25cm.

Place hold on Detection of autoantibodies against complement 1- q inpatients with chronic hepatitis C virus infection and extra - hepatic manifestations: Association with clinical and serological parameters /

.
180P : 25cm.

Place hold on Evaluation of different laboratory tests as predictors to the response for interferon therapy in chronic hepatitis C virus patients /

.
202P : 25cm.

Place hold on Gene expression profile of hepatocellular carcinoma and chronic active hepatitis /

.
91 P. : 25cm.

Place hold on Assessment of the presence of steatosis using Controlled Attenuation Parameter (CAP) and its effect on treatment outcome in Egyptian patients with chronic hepatitis C virus (HCV) treated with sofosbuvir based regimens /